Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Nontyphoidal Salmonella bacteremia

Elizabeth L Hohmann, MD
Section Editor
Stephen B Calderwood, MD
Deputy Editor
Allyson Bloom, MD


Nontyphoidal salmonellae are an important bacterial cause of diarrheal disease. The epidemiology and pathophysiology of nontyphoidal strains differ from typhoidal strains [1]. (See "Epidemiology, microbiology, clinical manifestations, and diagnosis of enteric (typhoid and paratyphoid) fever".)

Issues related to the epidemiology, clinical microbiology, clinical manifestations, and treatment of nontyphoidal Salmonella bacteremia will be reviewed here. Nontyphoidal Salmonella gastrointestinal disease and typhoid fever are discussed in detail separately. (See "Nontyphoidal Salmonella: Gastrointestinal infection and carriage" and "Treatment and prevention of enteric (typhoid and paratyphoid) fever".)


Incidence — Bacteremia and other forms of extraintestinal Salmonella infection are serious complications that may not be suspected in the setting of mild primary infection. The burden varies geographically. In a systematic review that extrapolated the global incidence of invasive nontyphoidal Salmonella infections based on 10 studies, there were an estimated 49 cases per 100,000 people worldwide in 2010 [2]. The greatest burden was in Africa, which had an estimated incidence of 227 cases per 100,000 people. Approximately 65 percent of cases worldwide are in children younger than five years.

It is estimated that perhaps 1 percent of enteric infections with nontyphoidal Salmonella result in bacteremia, but the true rate of bacteremia is unknown, as many primary enteric infections are mild or not microbiologically diagnosed.

Risk factors — Factors affecting the incidence of bacteremia include Salmonella serotype, geographic location, time of year, and host factors. Host risk factors for nontyphoidal Salmonella bacteremia include extremes of age and chronic or immunosuppressing conditions, including malignancy, rheumatological disease, TNF blockade (eg, agents such as etanercept or infliximab), transplantation, HIV infection, and congenital immune defects [3-6]. Other predisposing comorbidities include liver disease, hemoglobinopathies (especially sickle cell disease), schistosomiasis, and chronic granulomatous disease. Alteration of the GI tract also predisposes to progression from enteric to systemic salmonellosis (eg, by suppression of gastric acid, malnutrition, recent antibiotic use, or rotavirus infection) [7]. (See "Pathogenesis of Salmonella gastroenteritis".)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Mar 10, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Mandal BK, Brennand J. Bacteraemia in salmonellosis: a 15 year retrospective study from a regional infectious diseases unit. BMJ 1988; 297:1242.
  2. Ao TT, Feasey NA, Gordon MA, et al. Global burden of invasive nontyphoidal Salmonella disease, 2010(1). Emerg Infect Dis 2015; 21.
  3. Symmons DP, Silman AJ. The world of biologics. Lupus 2006; 15:122.
  4. Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009; 28:331.
  5. Katsarolis I, Tsiodras S, Panagopoulos P, et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005; 37:304.
  6. Gordon MA. Salmonella infections in immunocompromised adults. J Infect 2008; 56:413.
  7. Hung TY, Liu MC, Hsu CF, Lin YC. Rotavirus infection increases the risk of bacteremia in children with nontyphoid Salmonella gastroenteritis. Eur J Clin Microbiol Infect Dis 2009; 28:425.
  8. Dhanoa A, Fatt QK. Non-typhoidal Salmonella bacteraemia: epidemiology, clinical characteristics and its' association with severe immunosuppression. Ann Clin Microbiol Antimicrob 2009; 8:15.
  9. Gordon MA, Banda HT, Gondwe M, et al. Non-typhoidal salmonella bacteraemia among HIV-infected Malawian adults: high mortality and frequent recrudescence. AIDS 2002; 16:1633.
  10. Gordon MA, Graham SM, Walsh AL, et al. Epidemics of invasive Salmonella enterica serovar enteritidis and S. enterica Serovar typhimurium infection associated with multidrug resistance among adults and children in Malawi. Clin Infect Dis 2008; 46:963.
  11. Kariuki S, Revathi G, Kariuki N, et al. Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya. BMC Microbiol 2006; 6:101.
  12. Kariuki S, Revathi G, Kariuki N, et al. Invasive multidrug-resistant non-typhoidal Salmonella infections in Africa: zoonotic or anthroponotic transmission? J Med Microbiol 2006; 55:585.
  13. Sigaúque B, Roca A, Mandomando I, et al. Community-acquired bacteremia among children admitted to a rural hospital in Mozambique. Pediatr Infect Dis J 2009; 28:108.
  14. Krumkamp R, Kreuels B, Sarpong N, et al. Association Between Malaria and Invasive Nontyphoidal Salmonella Infection in a Hospital Study: Accounting for Berkson's Bias. Clin Infect Dis 2016; 62 Suppl 1:S83.
  15. Biggs HM, Lester R, Nadjm B, et al. Invasive Salmonella infections in areas of high and low malaria transmission intensity in Tanzania. Clin Infect Dis 2014; 58:638.
  16. Chau JY, Tiffany CM, Nimishakavi S, et al. Malaria-associated L-arginine deficiency induces mast cell-associated disruption to intestinal barrier defenses against nontyphoidal Salmonella bacteremia. Infect Immun 2013; 81:3515.
  17. Uche IV, MacLennan CA, Saul A. A Systematic Review of the Incidence, Risk Factors and Case Fatality Rates of Invasive Nontyphoidal Salmonella (iNTS) Disease in Africa (1966 to 2014). PLoS Negl Trop Dis 2017; 11:e0005118.
  18. Zaidi E, Bachur R, Harper M. Non-typhi Salmonella bacteremia in children. Pediatr Infect Dis J 1999; 18:1073.
  19. Shimoni Z, Pitlik S, Leibovici L, et al. Nontyphoid Salmonella bacteremia: age-related differences in clinical presentation, bacteriology, and outcome. Clin Infect Dis 1999; 28:822.
  20. Jones TF, Ingram LA, Cieslak PR, et al. Salmonellosis outcomes differ substantially by serotype. J Infect Dis 2008; 198:109.
  21. Rodríguez M, de Diego I, Martínez N, et al. Nontyphoidal Salmonella causing focal infections in patients admitted at a Spanish general hospital during an 11-year period (1991-2001). Int J Med Microbiol 2006; 296:211.
  22. Ramos JM, Aguado JM, García-Corbeira P, et al. Clinical spectrum of urinary tract infections due on nontyphoidal Salmonella species. Clin Infect Dis 1996; 23:388.
  23. Punpanich W, Netsawang S, Thippated C. Invasive salmonellosis in urban Thai children: a ten-year review. Pediatr Infect Dis J 2012; 31:e105.
  24. Sirinavin S, Chiemchanya S, Vorachit M. Systemic nontyphoidal Salmonella infection in normal infants in Thailand. Pediatr Infect Dis J 2001; 20:581.
  25. Molyneux EM, Mankhambo LA, Phiri A, et al. The outcome of non-typhoidal salmonella meningitis in Malawian children, 1997-2006. Ann Trop Paediatr 2009; 29:13.
  26. Keddy KH, Sooka A, Musekiwa A, et al. Clinical and Microbiological Features of Salmonella Meningitis in a South African Population, 2003-2013. Clin Infect Dis 2015; 61 Suppl 4:S272.
  27. Cohen PS, O'Brien TF, Schoenbaum SC, Medeiros AA. The risk of endothelial infection in adults with salmonella bacteremia. Ann Intern Med 1978; 89:931.
  28. Benenson S, Raveh D, Schlesinger Y, et al. The risk of vascular infection in adult patients with nontyphi Salmonella bacteremia. Am J Med 2001; 110:60.
  29. Hsu RB, Lin FY. Risk factors for bacteraemia and endovascular infection due to non-typhoid salmonella: a reappraisal. QJM 2005; 98:821.
  30. Cheng WL, Li CW, Li MC, et al. Salmonella infective endocarditis. J Microbiol Immunol Infect 2016; 49:313.
  31. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196.
  32. Leibovitz E. The use of fluoroquinolones in children. Curr Opin Pediatr 2006; 18:64.
  33. Stevenson JE, Gay K, Barrett TJ, et al. Increase in nalidixic acid resistance among non-Typhi Salmonella enterica isolates in the United States from 1996 to 2003. Antimicrob Agents Chemother 2007; 51:195.
  34. Humphries RM, Fang FC, Aarestrup FM, Hindler JA. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: recent changes to CLSI standards. Clin Infect Dis 2012; 55:1107.
  35. Lee HY, Su LH, Tsai MH, et al. High rate of reduced susceptibility to ciprofloxacin and ceftriaxone among nontyphoid Salmonella clinical isolates in Asia. Antimicrob Agents Chemother 2009; 53:2696.
  36. Angelo KM, Reynolds J, Karp BE, et al. Antimicrobial Resistance Among Nontyphoidal Salmonella Isolated From Blood in the United States, 2003-2013. J Infect Dis 2016; 214:1565.
  37. Iwamoto M, Reynolds J, Karp BE, et al. Ceftriaxone-Resistant Nontyphoidal Salmonella from Humans, Retail Meats, and Food Animals in the United States, 1996-2013. Foodborne Pathog Dis 2017; 14:74.
  38. Jean SS, Lee YT, Guo SM, Hsueh PR. Recurrent infections caused by cefotaxime- and ciprofloxacin-resistant Salmonella enterica serotype choleraesuis treated successfully with imipenem. J Infect 2005; 51:e163.
  39. Li WC, Huang FY, Liu CP, et al. Ceftriaxone resistance of nontyphoidal Salmonella enterica isolates in Northern Taiwan attributable to production of CTX-M-14 and CMY-2 beta-lactamases. J Clin Microbiol 2005; 43:3237.
  40. Miriagou V, Tzouvelekis LS, Rossiter S, et al. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47:1297.
  41. Day MR, Meunier D, Doumith M, et al. Carbapenemase-producing Salmonella enterica isolates in the UK. J Antimicrob Chemother 2015; 70:2165.
  42. Vlieghe ER, Phe T, De Smet B, et al. Azithromycin and ciprofloxacin resistance in Salmonella bloodstream infections in Cambodian adults. PLoS Negl Trop Dis 2012; 6:e1933.
  43. Oskoui R, Davis WA, Gomes MN. Salmonella aortitis. A report of a successfully treated case with a comprehensive review of the literature. Arch Intern Med 1993; 153:517.
  44. Lee CH, Hsieh HC, Ko PJ, et al. Treatment of infected abdominal aortic aneurysm caused by Salmonella. Ann Vasc Surg 2014; 28:217.
  45. Chen PL, Chang CM, Wu CJ, et al. Extraintestinal focal infections in adults with nontyphoid Salmonella bacteraemia: predisposing factors and clinical outcome. J Intern Med 2007; 261:91.
  46. Sörelius K, Mani K, Björck M, et al. Endovascular treatment of mycotic aortic aneurysms: a European multicenter study. Circulation 2014; 130:2136.
  47. Hsu RB, Lin FY. Nontyphoid Salmonella infection in heart transplant recipients. Am J Med Sci 2008; 336:393.
  48. Dhar JM, al-Khader AA, al-Sulaiman M, al-Hasani MK. Non-typhoid Salmonella in renal transplant recipients: a report of twenty cases and review of the literature. Q J Med 1991; 78:235.